BCR ligation with anti-IgM treatment also increases CD52+ MV release by CLL B cells, although the total amount of MVs was not significantly influenced by ibrutinib treatment of CLL cells in vitro [45]. Here, BCR is linked to B-cell chronic lymphocytic leukemia.